Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
Booster dose
Heterologous boosting
Recombinant Vaccine
SARS-CoV-2
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
20 Feb 2024
20 Feb 2024
Historique:
received:
08
02
2023
accepted:
12
02
2024
medline:
21
2
2024
pubmed:
21
2
2024
entrez:
20
2
2024
Statut:
epublish
Résumé
The immunity induced by primary vaccination is effective against COVID-19; however, booster vaccines are needed to maintain vaccine-induced immunity and improve protection against emerging variants. Heterologous boosting is believed to result in more robust immune responses. This study investigated the safety and immunogenicity of the Razi Cov Pars vaccine (RCP) as a heterologous booster dose in people primed with Beijing Bio-Institute of Biological Products Coronavirus Vaccine (BBIBP-CorV). We conducted a randomized, double-blind, active-controlled trial in adults aged 18 and over primarily vaccinated with BBIBP-CorV, an inactivated SARS-CoV-2 vaccine. Eligible participants were randomly assigned (1:1) to receive a booster dose of RCP or BBIBP-CorV vaccines. The primary outcome was neutralizing antibody activity measured by a conventional virus neutralization test (cVNT). The secondary efficacy outcomes included specific IgG antibodies against SARS-CoV-2 spike (S1 and receptor-binding domain, RBD) antigens and cell-mediated immunity. We measured humoral antibody responses at 2 weeks (in all participants) and 3 and 6 months (a subgroup of 101 participants) after the booster dose injection. The secondary safety outcomes were solicited and unsolicited immediate, local, and systemic adverse reactions. We recruited 483 eligible participants between December 7, 2021, and January 13, 2022. The mean age was 51.9 years, and 68.1% were men. Neutralizing antibody titers increased about 3 (geometric mean fold increase, GMFI = 2.77, 95% CI 2.26-3.39) and 21 (GMFI = 21.51, 95% CI 16.35-28.32) times compared to the baseline in the BBIBP-CorV and the RCP vaccine groups. Geometric mean ratios (GMR) and 95% CI for serum neutralizing antibody titers for RCP compared with BBIBP-CorV on days 14, 90, and 180 were 6.81 (5.32-8.72), 1.77 (1.15-2.72), and 2.37 (1.62-3.47) respectively. We observed a similar pattern for specific antibody responses against S1 and RBD. We detected a rise in gamma interferon (IFN-γ), tumor necrosis factor (TNF-α), and interleukin 2 (IL-2) following stimulation with S antigen, particularly in the RCP group, and the flow cytometry examination showed an increase in the percentage of CD3 + /CD8 + lymphocytes. RCP and BBIBP-CorV had similar safety profiles; we identified no vaccine-related or unrelated deaths. BBIBP-CorV and RCP vaccines as booster doses are safe and provide a strong immune response that is more robust when the RCP vaccine is used. Heterologous vaccines are preferred as booster doses. This study was registered with the Iranian Registry of Clinical Trial at www.irct.ir , IRCT20201214049709N4. Registered 29 November 2021.
Sections du résumé
BACKGROUND
BACKGROUND
The immunity induced by primary vaccination is effective against COVID-19; however, booster vaccines are needed to maintain vaccine-induced immunity and improve protection against emerging variants. Heterologous boosting is believed to result in more robust immune responses. This study investigated the safety and immunogenicity of the Razi Cov Pars vaccine (RCP) as a heterologous booster dose in people primed with Beijing Bio-Institute of Biological Products Coronavirus Vaccine (BBIBP-CorV).
METHODS
METHODS
We conducted a randomized, double-blind, active-controlled trial in adults aged 18 and over primarily vaccinated with BBIBP-CorV, an inactivated SARS-CoV-2 vaccine. Eligible participants were randomly assigned (1:1) to receive a booster dose of RCP or BBIBP-CorV vaccines. The primary outcome was neutralizing antibody activity measured by a conventional virus neutralization test (cVNT). The secondary efficacy outcomes included specific IgG antibodies against SARS-CoV-2 spike (S1 and receptor-binding domain, RBD) antigens and cell-mediated immunity. We measured humoral antibody responses at 2 weeks (in all participants) and 3 and 6 months (a subgroup of 101 participants) after the booster dose injection. The secondary safety outcomes were solicited and unsolicited immediate, local, and systemic adverse reactions.
RESULTS
RESULTS
We recruited 483 eligible participants between December 7, 2021, and January 13, 2022. The mean age was 51.9 years, and 68.1% were men. Neutralizing antibody titers increased about 3 (geometric mean fold increase, GMFI = 2.77, 95% CI 2.26-3.39) and 21 (GMFI = 21.51, 95% CI 16.35-28.32) times compared to the baseline in the BBIBP-CorV and the RCP vaccine groups. Geometric mean ratios (GMR) and 95% CI for serum neutralizing antibody titers for RCP compared with BBIBP-CorV on days 14, 90, and 180 were 6.81 (5.32-8.72), 1.77 (1.15-2.72), and 2.37 (1.62-3.47) respectively. We observed a similar pattern for specific antibody responses against S1 and RBD. We detected a rise in gamma interferon (IFN-γ), tumor necrosis factor (TNF-α), and interleukin 2 (IL-2) following stimulation with S antigen, particularly in the RCP group, and the flow cytometry examination showed an increase in the percentage of CD3 + /CD8 + lymphocytes. RCP and BBIBP-CorV had similar safety profiles; we identified no vaccine-related or unrelated deaths.
CONCLUSIONS
CONCLUSIONS
BBIBP-CorV and RCP vaccines as booster doses are safe and provide a strong immune response that is more robust when the RCP vaccine is used. Heterologous vaccines are preferred as booster doses.
TRIAL REGISTRATION
BACKGROUND
This study was registered with the Iranian Registry of Clinical Trial at www.irct.ir , IRCT20201214049709N4. Registered 29 November 2021.
Identifiants
pubmed: 38378570
doi: 10.1186/s12916-024-03295-1
pii: 10.1186/s12916-024-03295-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
78Informations de copyright
© 2024. The Author(s).
Références
Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et al. Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines. 2022;10(1):86.
doi: 10.3390/vaccines10010086
pubmed: 35062747
pmcid: 8779615
WHO Coronavirus (COVID-19) Dashboard. 2022. https://covid19.who.int . Accessed 29 June 2022.
Li J-X, Wu S-P, Guo X-L, Tang R, Huang B-Y, Chen X-Q, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022;10(8):739–48.
doi: 10.1016/S2213-2600(22)00087-X
pubmed: 35605625
pmcid: 9122540
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626–36.
doi: 10.1038/s41577-021-00592-1
pubmed: 34373623
pmcid: 8351583
Sasikala M, Shashidhar J, Deepika G, Ravikanth V, Krishna VV, Sadhana Y, et al. Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals. Int J Infect Dis. 2021;108:183–6.
doi: 10.1016/j.ijid.2021.05.034
pubmed: 34022331
pmcid: 8132551
Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of protection against mild and severe disease by COVID-19 vaccines. NEJM. 2022;386(4):340–50.
doi: 10.1056/NEJMoa2115481
pubmed: 35021002
Low EV, Tok PSK, Husin M, Suah JL, Tng BH, Thevananthan T, et al. Assessment of heterologous and homologous boosting with inactivated COVID-19 vaccine at 3 months compared with homologous boosting of BNT162b2 at 6 months. JAMA Netw. 2022;5(8):e2226046.
doi: 10.1001/jamanetworkopen.2022.26046
Mallory RM, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2022;22(11):1565–76.
doi: 10.1016/S1473-3099(22)00420-0
pubmed: 35963274
pmcid: 9365313
Suah JL, Husin M, Tok PSK, Tng BH, Thevananthan T, Low EV, et al. Waning COVID-19 vaccine effectiveness for BNT162b2 and CoronaVac in Malaysia: an observational study. Int J Infect Dis. 2022;119:69–76.
doi: 10.1016/j.ijid.2022.03.028
pubmed: 35331933
pmcid: 8938298
Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes CdFR, Lind ML, et al. Effectiveness of an inactivated COVID-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nat Commun. 2022;13(1):5536.
doi: 10.1038/s41467-022-33169-0
pubmed: 36202800
pmcid: 9537178
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet (London, England). 2021;398(10318):2258–76.
doi: 10.1016/S0140-6736(21)02717-3
pubmed: 34863358
Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, et al. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nat Commun. 2022;13(1):3654.
doi: 10.1038/s41467-022-31379-0
pubmed: 35760812
pmcid: 9237056
Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399(10324):521–9.
doi: 10.1016/S0140-6736(22)00094-0
pubmed: 35074136
pmcid: 8782575
Jara A, Undurraga EA, Zubizarreta JR, González C, Pizarro A, Acevedo J, et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health. 2022;10(6):e798–806.
doi: 10.1016/S2214-109X(22)00112-7
pubmed: 35472300
pmcid: 9034854
Kaabi NA, Yang YK, Zhang J, Xu K, Liang Y, Kang Y, et al. Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. Signal Transduct Target Ther. 2022;7(1):172.
doi: 10.1038/s41392-022-00984-2
pubmed: 35665745
pmcid: 9167817
Cao Y, Hao X, Wang X, Wu Q, Song R, Zhao D, et al. Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine. Cell Res. 2022;32(1):107–9.
doi: 10.1038/s41422-021-00596-5
pubmed: 34862467
Wang XY, Mahmood SF, Jin F, Cheah WK, Ahmad M, Sohail MA, et al. Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial. Emerg Microbes Infect. 2022;11(1):1910–9.
doi: 10.1080/22221751.2022.2088406
pubmed: 35686572
pmcid: 9347473
Tabarsi P, Anjidani N, Shahpari R, Roshanzamir K, Fallah N, Andre G, et al. Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: a randomized placebo-controlled trial. Immunology. 2022;167(3):340–53.
doi: 10.1111/imm.13540
pubmed: 35758850
Kovalenko A, Ryabchevskaya E, Evtushenko E, Nikitin N, Karpova O. Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress. Int J Mol Sci. 2023;24(2):1701.
doi: 10.3390/ijms24021701
pubmed: 36675218
pmcid: 9863728
Dodaran MS, Banihashemi SR, Es-haghi A, Mehrabadi MHF, Nofeli M, Mokarram AR, et al. Immunogenicity and safety of a combined intramuscular/intranasal recombinant spike protein COVID-19 vaccine (RCP) in healthy adults aged 18 to 55 years old: a randomized, double-blind, placebo-controlled, phase I trial. Vaccines. 2023;11(2):455.
doi: 10.3390/vaccines11020455
pubmed: 36851334
pmcid: 9961243
Banihashemi SR, Es-Haghi A, Fallah Mehrabadi MH, Nofeli M, Mokarram AR, Ranjbar A, et al. Safety and efficacy of combined intramuscular/intranasal RAZI-COV PARS vaccine candidate against SARS-CoV-2: a preclinical study in several animal models. Front Immunol. 2022;13:836745.
doi: 10.3389/fimmu.2022.836745
pubmed: 35693788
pmcid: 9179012
Mohazzab A, Fallah Mehrabadi MH, Es-Haghi A, Kalantari S, Mokhberalsafa L, Setarehdan SA, et al. Phase II, safety and immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 vaccine in adults aged 18–70 years; a randomized, double-blind clinical trial. J Pharm Sci. 2023;112(12):3012–21.
doi: 10.1016/j.xphs.2023.09.027
pubmed: 37832918
COVID-19 situation reports_ Islamic Repblic of Iran: WHO Regional Office for the Eastern Mediterranean; 2022. https://www.emro.who.int/images/stories/iran/covid-19-sit-reps/COVID-19-Update-220924.pdf?ua=1 . Accessed 20 Dec 2022.
Yu X, Wei D, Xu W, Liu C, Guo W, Li X, et al. Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. Nat Commun. 2022;13(1):1788.
doi: 10.1038/s41467-022-29477-0
pubmed: 35379815
pmcid: 8980020
Badano MN, Sabbione F, Keitelman I, Pereson M, Aloisi N, Colado A, et al. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2. Mol Immunol. 2022;143:94–9.
doi: 10.1016/j.molimm.2022.01.009
pubmed: 35091231
pmcid: 8761547
Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022;22(4):483–95.
doi: 10.1016/S1473-3099(21)00681-2
pubmed: 34890537
He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004;324(2):773–81.
doi: 10.1016/j.bbrc.2004.09.106
pubmed: 15474494
pmcid: 7092904
Food and Drug Administration. Guidance for Industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf . Accessed 15 Dec 2022.
The use of the WHO-UMC system for standardised case causality assessment .2013. https://www.who.int/publications/m/item/WHO-causality-assessment . Accessed 30 June 2022.
Yaugel-Novoa M, Bourlet T, Paul S. Role of the humoral immune response during COVID-19: guilty or not guilty? Mucosal Immunol. 2022;15(6):1170–80.
doi: 10.1038/s41385-022-00569-w
pubmed: 36195658
pmcid: 9530436
Jaggaiahgari S, Munigela A, Mitnala S, Gujjarlapudi D, Simhadri V, Nageshwar RD. Heterologous booster dose with CORBEVAX following primary vaccination with COVISHIELD enhances protection against SARS-CoV-2. Vaccines. 2022;10(12):2146.
doi: 10.3390/vaccines10122146
pubmed: 36560556
pmcid: 9781398
Zhang N, Li K, Liu Z, Nandakumar KS, Jiang S. A perspective on the roles of adjuvants in developing highly potent COVID-19 vaccines. Viruses. 2022;14(2):387.
doi: 10.3390/v14020387
pubmed: 35215980
pmcid: 8875727
Peng S, Cao F, Xia Y, Gao X-D, Dai L, Yan J, et al. Particulate alum via pickering emulsion for an enhanced COVID-19 vaccine adjuvant. Adv Mater. 2020;32(40):2004210.
doi: 10.1002/adma.202004210
Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S, et al. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine. 2022;77:103904.
doi: 10.1016/j.ebiom.2022.103904
pubmed: 35248996
pmcid: 8893246
Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. NEJM. 2021;385(19):1761–73.
doi: 10.1056/NEJMoa2110345
pubmed: 34525277
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11.
doi: 10.1038/s41591-021-01377-8
pubmed: 34002089
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51.
doi: 10.1016/S1473-3099(20)30831-8
pubmed: 33069281